Clevidipine

DB04920

small molecule approved investigational

Deskripsi

Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.

Struktur Molekul 2D

Berat 456.316
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 1 minute
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Clevidipine is rapidly hydrolyzed to inactive metabolites by esterases in arterial blood.

Rute Eliminasi

urine 63-74%, feces 7-22%

Interaksi Obat

1752 Data
Duloxetine The risk or severity of orthostatic hypotension and syncope can be increased when Clevidipine is combined with Duloxetine.
Levodopa The risk or severity of hypotension and orthostatic hypotension can be increased when Clevidipine is combined with Levodopa.
Risperidone Clevidipine may increase the hypotensive activities of Risperidone.
Lomitapide The metabolism of Lomitapide can be decreased when combined with Clevidipine.
Ceritinib Clevidipine may increase the bradycardic activities of Ceritinib.
Ivabradine Clevidipine may increase the bradycardic activities of Ivabradine.
Ruxolitinib Ruxolitinib may increase the bradycardic activities of Clevidipine.
Aripiprazole The metabolism of Aripiprazole can be increased when combined with Clevidipine.
Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be increased when combined with Clevidipine.
Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Clevidipine.
Eliglustat The metabolism of Eliglustat can be decreased when combined with Clevidipine.
Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Clevidipine.
Colchicine The metabolism of Colchicine can be decreased when combined with Clevidipine.
Fentanyl Fentanyl may increase the bradycardic activities of Clevidipine.
Iloperidone The metabolism of Iloperidone can be decreased when combined with Clevidipine.
Retapamulin The metabolism of Retapamulin can be decreased when combined with Clevidipine.
Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Clevidipine.
Vardenafil The metabolism of Vardenafil can be decreased when combined with Clevidipine.
Zopiclone The metabolism of Zopiclone can be decreased when combined with Clevidipine.
Lovastatin The metabolism of Lovastatin can be decreased when combined with Clevidipine.
Cimetidine The serum concentration of Clevidipine can be increased when it is combined with Cimetidine.
Clopidogrel The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Clevidipine.
Efavirenz The serum concentration of Clevidipine can be decreased when it is combined with Efavirenz.
Melatonin The therapeutic efficacy of Clevidipine can be decreased when used in combination with Melatonin.
Nafcillin The therapeutic efficacy of Clevidipine can be decreased when used in combination with Nafcillin.
Nitroprusside Clevidipine may increase the hypotensive activities of Nitroprusside.
Dantrolene The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Clevidipine.
Lithium citrate The risk or severity of adverse effects can be increased when Clevidipine is combined with Lithium citrate.
Lithium carbonate The risk or severity of adverse effects can be increased when Clevidipine is combined with Lithium carbonate.
Lithium hydroxide The risk or severity of adverse effects can be increased when Clevidipine is combined with Lithium hydroxide.
Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Clevidipine.
Alprazolam The metabolism of Alprazolam can be decreased when combined with Clevidipine.
Tacrine Tacrine may increase the neuromuscular blocking activities of Clevidipine.
Sulpiride Sulpiride may increase the neuromuscular blocking activities of Clevidipine.
Profenamine Profenamine may increase the neuromuscular blocking activities of Clevidipine.
Triflupromazine Triflupromazine may increase the neuromuscular blocking activities of Clevidipine.
Cinchocaine Cinchocaine may increase the neuromuscular blocking activities of Clevidipine.
Nizatidine Nizatidine may increase the neuromuscular blocking activities of Clevidipine.
Isoflurophate Isoflurophate may increase the neuromuscular blocking activities of Clevidipine.
Diethylcarbamazine Diethylcarbamazine may increase the neuromuscular blocking activities of Clevidipine.
Mechlorethamine Mechlorethamine may increase the neuromuscular blocking activities of Clevidipine.
Hexafluronium Hexafluronium may increase the neuromuscular blocking activities of Clevidipine.
Demecarium Demecarium may increase the neuromuscular blocking activities of Clevidipine.
Physostigmine Physostigmine may increase the neuromuscular blocking activities of Clevidipine.
Ambenonium Ambenonium may increase the neuromuscular blocking activities of Clevidipine.
Decamethonium Decamethonium may increase the neuromuscular blocking activities of Clevidipine.
Ginkgo biloba Ginkgo biloba may increase the neuromuscular blocking activities of Clevidipine.
Neostigmine Neostigmine may increase the neuromuscular blocking activities of Clevidipine.
Bambuterol Bambuterol may increase the neuromuscular blocking activities of Clevidipine.
1,10-Phenanthroline 1,10-Phenanthroline may increase the neuromuscular blocking activities of Clevidipine.
Huperzine A Huperzine A may increase the neuromuscular blocking activities of Clevidipine.
Phenserine Phenserine may increase the neuromuscular blocking activities of Clevidipine.
Regramostim Regramostim may increase the neuromuscular blocking activities of Clevidipine.
Aprotinin Aprotinin may increase the neuromuscular blocking activities of Clevidipine.
Betaine Betaine may increase the neuromuscular blocking activities of Clevidipine.
Coumaphos Coumaphos may increase the neuromuscular blocking activities of Clevidipine.
Dichlorvos Dichlorvos may increase the neuromuscular blocking activities of Clevidipine.
Fenthion Fenthion may increase the neuromuscular blocking activities of Clevidipine.
Metrifonate Metrifonate may increase the neuromuscular blocking activities of Clevidipine.
Acotiamide Acotiamide may increase the neuromuscular blocking activities of Clevidipine.
Methanesulfonyl Fluoride Methanesulfonyl Fluoride may increase the neuromuscular blocking activities of Clevidipine.
Paraoxon Paraoxon may increase the neuromuscular blocking activities of Clevidipine.
Tyrothricin Tyrothricin may increase the neuromuscular blocking activities of Clevidipine.
Ipidacrine Ipidacrine may increase the neuromuscular blocking activities of Clevidipine.
Distigmine Distigmine may increase the neuromuscular blocking activities of Clevidipine.
Tretamine Tretamine may increase the neuromuscular blocking activities of Clevidipine.
Posiphen Posiphen may increase the neuromuscular blocking activities of Clevidipine.
Galantamine Galantamine may increase the neuromuscular blocking activities of Clevidipine.
Terbutaline Terbutaline may increase the neuromuscular blocking activities of Clevidipine.
Edrophonium Edrophonium may increase the neuromuscular blocking activities of Clevidipine.
Memantine Memantine may increase the neuromuscular blocking activities of Clevidipine.
Ketamine Ketamine may increase the neuromuscular blocking activities of Clevidipine.
Pyridostigmine Pyridostigmine may increase the neuromuscular blocking activities of Clevidipine.
Rivastigmine Rivastigmine may increase the neuromuscular blocking activities of Clevidipine.
Methylphosphinic Acid Methylphosphinic Acid may increase the neuromuscular blocking activities of Clevidipine.
Mefloquine Mefloquine may increase the neuromuscular blocking activities of Clevidipine.
Pegvisomant Pegvisomant may increase the neuromuscular blocking activities of Clevidipine.
Capsaicin Capsaicin may increase the neuromuscular blocking activities of Clevidipine.
Ifosfamide The metabolism of Ifosfamide can be increased when combined with Clevidipine.
Perampanel The metabolism of Perampanel can be increased when combined with Clevidipine.
Warfarin The serum concentration of Warfarin can be increased when it is combined with Clevidipine.
Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Clevidipine.
(R)-warfarin The serum concentration of (R)-warfarin can be increased when it is combined with Clevidipine.
R,S-Warfarin alcohol The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Clevidipine.
S,R-Warfarin alcohol The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Clevidipine.
(S)-Warfarin The serum concentration of (S)-Warfarin can be increased when it is combined with Clevidipine.
Midazolam The serum concentration of Midazolam can be increased when it is combined with Clevidipine.
Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Clevidipine.
Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Clevidipine.
Mirabegron The serum concentration of Clevidipine can be increased when it is combined with Mirabegron.
Boceprevir The serum concentration of Clevidipine can be increased when it is combined with Boceprevir.
Nicorandil Nicorandil may increase the hypotensive activities of Clevidipine.
Hyoscyamine Hyoscyamine may increase the arrhythmogenic activities of Clevidipine.
Atropine Atropine may increase the arrhythmogenic activities of Clevidipine.
Adenosine Adenosine may increase the arrhythmogenic activities of Clevidipine.
Moricizine Moricizine may increase the arrhythmogenic activities of Clevidipine.
Tocainide Tocainide may increase the arrhythmogenic activities of Clevidipine.
Ajmaline Ajmaline may increase the arrhythmogenic activities of Clevidipine.
Carteolol Clevidipine may increase the arrhythmogenic activities of Carteolol.
Metipranolol Clevidipine may increase the arrhythmogenic activities of Metipranolol.

Target Protein

Voltage-dependent L-type calcium channel subunit alpha-1F CACNA1F
Voltage-dependent L-type calcium channel subunit alpha-1S CACNA1S
Voltage-dependent L-type calcium channel subunit alpha-1D CACNA1D
Voltage-dependent L-type calcium channel subunit alpha-1C CACNA1C

Referensi & Sumber

Artikel (PubMed)
  • PMID: 16501008
    Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24.
  • PMID: 15492770
    Nordlander M, Sjoquist PO, Ericsson H, Ryden L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004 Fall;22(3):227-50.
  • PMID: 12131552
    Wang QD, Segawa D, Ericsson H, Sjoquist PO, Johansson L, Ryden L: Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I. J Cardiovasc Pharmacol. 2002 Aug;40(2):228-34.
  • PMID: 12069360
    Stephens CT, Jandhyala BS: Effects of fenoldopam, a dopamine D-1 agonist, and clevidipine, a calcium channel antagonist, in acute renal failure in anesthetized rats. Clin Exp Hypertens. 2002 May;24(4):301-13.

Contoh Produk & Brand

Produk: 7 • International brands: 0
Produk
  • Cleviprex
    Emulsion • 0.5 mg/1mL • Intravenous • US • Approved
  • Cleviprex
    Emulsion • 0.5 mg/1mL • Intravenous • US • Approved
  • Cleviprex
    Emulsion • 0.5 mg/1mL • Intravenous • US • Approved
  • Cleviprex
    Emulsion • 0.5 mg/1mL • Intravenous • US • Approved
  • Cleviprex
    Emulsion • 0.5 mg / mL • Intravenous • Canada • Approved
  • Cleviprex
    Emulsion • 0.5 mg/1mL • Intravenous • US • Approved
  • Cleviprex
    Emulsion • 0.5 mg/1mL • Intravenous • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul